Stay updated with breaking news from Seroba Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
STC-15 is the first METTL3 inhibitor to enter clinical development Clinical data will include safety, pharmacology, target modulation, and clinical activity CAMBRIDGE, England, May
/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting...
17 Oct 2023 STORM's first-in-class investigational drug STC-15 is the first clinical stage molecule specifically targeting an RNA methyltransferase ...
/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA...
Shorla Oncology has raised $35m in a Series B funding round to progress its oncology product portfolio.